When is the next results date for Wockhardt?

No Upcoming Board Meetings

Who are in the management team of Wockhardt?

As of March 2023, Wockhardt's management team includes H F Khorakiwala (Executive Chairman), Murtaza H Khorakiwala (Managing Director), Huzaifa H Khorakiwala (Executive Director), and Rashmi Mamtura (Company Secretary). The board also features independent directors and Zahabiya Khorakiwala as a Non-Executive Director.

As of March 2023, the management team of Wockhardt includes the following individuals:<BR><BR>1. H F Khorakiwala - Executive Chairman<BR>2. Murtaza H Khorakiwala - Managing Director<BR>3. Huzaifa H Khorakiwala - Executive Director<BR>4. Rashmi Mamtura - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent directors, including Aman Mehta, Sanjaya Baru, D S Brar, Tasneem Mehta, Vinesh Kumar Jairath, Akhilesh Gupta, and Amelia Fernandes. Zahabiya Khorakiwala serves as a Non-Executive & Non-Independent Director. <BR><BR>This composition reflects a mix of executive leadership and independent oversight within the company.

What does Wockhardt do?

Wockhardt Ltd is a global pharmaceutical and biotechnology company that offers affordable medicines and operates advanced hospitals. As of March 2025, it reported net sales of 743 Cr and a net profit of -25 Cr, with a market cap of Rs 24,371 Cr.

Overview: <BR>Wockhardt Ltd is a global pharmaceutical and biotechnology organization that provides affordable, high-quality medicines and operates advanced Super Speciality Hospitals, categorized as a Large Cap company in the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Wockhardt Limited was incorporated in July 1999. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 743 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -25 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 24,371 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.32 <BR>Return on Equity: -1.08% <BR>Price to Book: 5.71<BR><BR>Contact Details: <BR>Address: D-4 MIDC, Chikalthana Aurangabad, Maharashtra: 431006 <BR>Tel: 91-240-6694444 <BR>Email: investorrelations@wockhardt.com <BR>Website: http://www.wockhardt.com

Has Wockhardt declared dividend?

Wockhardt Ltd has declared a 200% dividend, amounting to ₹10 per share, with an ex-date of November 17, 2016. Despite this declaration, the dividend yield is 0%, but the company has shown strong price returns over various periods.

Wockhardt Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 10<BR>- Ex-date: 17 Nov 16<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 7.93%, with no dividend return, resulting in a total return of 7.93%.<BR><BR>For the 1-year period, the price return was 175.15%, with no dividend return, leading to a total return of 175.15%.<BR><BR>Over the 2-year period, the price return was 753.73%, with no dividend return, culminating in a total return of 753.73%.<BR><BR>In the 3-year period, the price return was 470.67%, with no dividend return, resulting in a total return of 470.67%.<BR><BR>For the 4-year period, the price return was 129.39%, with no dividend return, leading to a total return of 129.39%.<BR><BR>In the 5-year period, the price return was 484.34%, with no dividend return, culminating in a total return of 484.34%.<BR><BR>Overall, Wockhardt has declared a significant dividend, but the dividend yield remains at 0%. The total returns over various periods indicate strong price performance, particularly over longer time frames, despite the lack of ongoing dividend returns since the last declaration.

Who are the peers of the Wockhardt?

Wockhardt's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca, ERIS Lifescience, OneSource Specialty, Alembic Pharma, and Jubilant Pharma. Wockhardt has a good growth rating and the highest 1-year return at 174.38% among its peers.

Peers: The peers of Wockhardt are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, ERIS Lifescience, OneSource Speci., Alembic Pharma, and Jubilant Pharmo.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Astrazeneca Phar, ERIS Lifescience, and OneSource Speci., while Good management risk is found at Divi's Lab., Torrent Pharma, Wockhardt, and Alembic Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and OneSource Speci., while Good growth is noted for Wockhardt. Below Average growth is seen at Divi's Lab., Torrent Pharma, Astrazeneca Phar, ERIS Lifescience, Alembic Pharma, and Jubilant Pharmo. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Astrazeneca Phar, and ERIS Lifescience, while Good capital structure is found at Torrent Pharma, Average at Jubilant Pharmo, and Below Average at Wockhardt and OneSource Speci.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 174.38%, while the lowest is Sun Pharma.Inds. at 14.97%. Wockhardt's 1-year return significantly exceeds that of all its peers. Additionally, the peers with negative six-month returns include Torrent Pharma and Alembic Pharma.

Who are the top shareholders of the Wockhardt?

The top shareholders of Wockhardt include Themisto Trustee Company Private Limited with 40.15%, mutual funds at 7.56%, foreign institutional investors at 6.81%, and Rekha Jhunjhunwala as the largest public shareholder with 1.75%. Individual investors collectively own 26.69% of the shares.

The top shareholders of Wockhardt include the promoters, who hold the majority of the shares. The promoter with the highest holding is Themisto Trustee Company Private Limited, which owns 40.15% of the company. Additionally, there are mutual funds that collectively hold 7.56% of the shares, and foreign institutional investors (FIIs) hold 6.81%. The highest public shareholder is Rekha Jhunjhunwala, with a stake of 1.75%. Individual investors collectively hold 26.69% of the shares.

How big is Wockhardt?

As of 24th July, Wockhardt Ltd has a market capitalization of 27,857.00 Cr and reported net sales of 3,012.00 Cr, with a loss of 47.00 Cr in the latest four quarters. The company has shareholder's funds of 4,353.00 Cr and total assets of 7,586.00 Cr.

As of 24th July, Wockhardt Ltd has a market capitalization of 27,857.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Wockhardt reported net sales of 3,012.00 Cr. However, the company experienced a loss of 47.00 Cr during the same period.<BR><BR>The latest annual reporting period shows that Wockhardt has shareholder's funds amounting to 4,353.00 Cr and total assets of 7,586.00 Cr.

Are Wockhardt latest results good or bad?

Wockhardt's latest results are concerning, showing a consolidated net loss of ₹90 crores, a 260% increase from the previous quarter and a 543% decline year-on-year, despite stable net sales. This indicates significant financial challenges and structural issues within the company.

Wockhardt's latest results indicate a challenging situation for the company. In the most recent quarter, the company reported a consolidated net loss of ₹90 crores, which represents a significant deterioration of 260% compared to the previous quarter and a staggering 543% year-on-year decline. This sharp increase in losses raises serious concerns about the company's financial health.<BR><BR>While net sales remained relatively stable at ₹738 crores, showing only a slight decline of 0.67% quarter-on-quarter and 0.14% year-on-year, the stagnation in revenue highlights Wockhardt's struggle to grow in a competitive pharmaceutical market. The operating margin did improve slightly to 9.76%, indicating some success in cost management, but this was overshadowed by the substantial losses at the bottom line.<BR><BR>Overall, the results reflect deeper structural issues within the company, including high interest costs and operational inefficiencies, which are preventing it from achieving profitability. The combination of persistent losses, weak return metrics, and high leverage suggests that Wockhardt is facing significant challenges that could impact its long-term viability. Therefore, the latest results can be characterized as bad, with urgent attention needed to address these ongoing issues.

How has been the historical performance of Wockhardt?

Wockhardt's net sales increased to 3,012.00 Cr in March 2025, up from 2,651.00 Cr in March 2023, but profitability remains a concern with a profit before tax of -16.00 Cr and a profit after tax loss of -57.00 Cr. Total liabilities rose to 7,586.00 Cr, and cash flow from operating activities was negative at -22.00 Cr, indicating ongoing financial challenges despite sales recovery.

Answer:<BR>The historical performance of Wockhardt has shown significant fluctuations over the years, particularly in net sales and profitability. In March 2025, net sales reached 3,012.00 Cr, an increase from 2,798.00 Cr in March 2024 and 2,651.00 Cr in March 2023, although still below the 3,230.00 Cr recorded in March 2022. The total operating income followed a similar trend, peaking at 3,012.00 Cr in March 2025. However, the company faced challenges with profitability, as the profit before tax was -16.00 Cr in March 2025, an improvement from -420.00 Cr in March 2024 but still indicative of ongoing financial struggles. The profit after tax also showed a loss of -57.00 Cr in March 2025, although this was less severe than the losses of -472.00 Cr and -621.00 Cr in the previous two years. <BR><BR>On the balance sheet, total liabilities increased to 7,586.00 Cr in March 2025 from 7,070.00 Cr in March 2024, while total assets also rose to 7,586.00 Cr. The company's cash flow from operating activities was negative at -22.00 Cr in March 2025, contrasting with a positive cash flow of 219.00 Cr in March 2024. Overall, while Wockhardt has seen some recovery in sales, its profitability remains a concern, and the company continues to navigate significant financial challenges.<BR><BR>Breakdown:<BR>Wockhardt's net sales have shown a positive trend, increasing from 2,651.00 Cr in March 2023 to 3,012.00 Cr in March 2025, although this is still below the 3,230.00 Cr recorded in March 2022. The total operating income mirrored this growth, reaching 3,012.00 Cr in March 2025. Despite the rise in sales, profitability remains a significant issue, with profit before tax improving to -16.00 Cr in March 2025 from -420.00 Cr in March 2024, yet still indicating a loss. The profit after tax also reflected a loss of -57.00 Cr in March 2025, although this was an improvement from the previous two years. On the balance sheet, total liabilities increased to 7,586.00 Cr in March 2025, while total assets matched this figure. Cash flow from operating activities was negative at -22.00 Cr in March 2025, contrasting with a positive cash flow of 219.00 Cr in March 2024, highlighting ongoing financial challenges despite some recovery in sales.

Is Wockhardt technically bullish or bearish?

As of December 1, 2025, Wockhardt's technical trend is mildly bearish, influenced by bearish weekly MACD and KST indicators, despite some bullish signals from Bollinger Bands and strong long-term returns compared to the Sensex.

As of 1 December 2025, the technical trend for Wockhardt has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and KST indicators, both of which are bearish. The daily moving averages also reflect a mildly bearish outlook. While the Bollinger Bands indicate bullishness on both weekly and monthly time frames, the overall sentiment remains cautious due to the lack of strong signals from the RSI and the Dow Theory showing no trend on a weekly basis. The stock has shown strong returns over the 3-year and 5-year periods compared to the Sensex, but the recent performance is not enough to shift the current mildly bearish stance.

Should I buy, sell or hold Wockhardt?

Why is Wockhardt falling/rising?

As of 02-Dec, Wockhardt Ltd's stock price is rising to 1,494.75, reflecting a 1.62% increase. This positive trend is supported by strong recent performance, significant investor interest, and impressive financial growth, despite some long-term concerns.

As of 02-Dec, Wockhardt Ltd's stock price is rising, currently at 1,494.75, which reflects an increase of 23.85 (1.62%). This upward movement can be attributed to several positive factors. Over the past week, the stock has outperformed the Sensex, gaining 17.57% compared to the index's 0.65%. Additionally, in the last two days alone, Wockhardt has seen a remarkable return of 21.17%. <BR><BR>The stock has also reached an intraday high of Rs 1566.95, marking a 6.53% increase during the trading day. Furthermore, Wockhardt is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend. <BR><BR>Investor participation has significantly increased, with delivery volume on December 1 rising by 1059.47% against the 5-day average, suggesting heightened interest in the stock. The company's recent financial performance has also been impressive, with a 116.3% growth in operating profit and a substantial increase in profit after tax (PAT) of 336.11% over the last six months. <BR><BR>Despite some concerns regarding long-term fundamentals, such as a low return on capital employed (ROCE) and high debt levels, the immediate market sentiment appears positive, driven by strong recent performance and investor confidence.

Which are the latest news on Wockhardt?

Is Wockhardt overvalued or undervalued?

As of December 3, 2025, Wockhardt is considered expensive with a PE ratio of 310.74 and an EV to EBITDA of 55.48, significantly higher than its peers, indicating it is overvalued despite a strong stock return of 480.69% over the past three years.

As of 3 December 2025, Wockhardt's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on its current financial metrics. The PE ratio stands at an astonishing 310.74, while the EV to EBITDA ratio is 55.48, both significantly higher than its peers. Additionally, the ROCE is only 3.69%, and the ROE is a mere 1.62%, suggesting inefficiencies in generating returns relative to its equity.<BR><BR>In comparison to its peers, Wockhardt's valuation metrics are starkly higher; for instance, Sun Pharma has a PE ratio of 37.51 and an EV to EBITDA of 24.8, while Cipla, which is rated attractive, has a PE of 22.39 and an EV to EBITDA of 15.83. These figures highlight that Wockhardt is not only expensive relative to its direct competitors but also lacks the financial performance to justify such high valuations. Despite a strong performance over the past three years with a stock return of 480.69%, the overall valuation suggests that Wockhardt is overvalued in the current market context.